Half-year report · Q2
8129.TEDINET S100URS6
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥755.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥1.48T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥734.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥21.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥770.7bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥773.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥801.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥508.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥524.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥262.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥249.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥245.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥108.2bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥133.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥103.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥133.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥59.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥53.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥10.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥85.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥320.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.19 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥75.64 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥286.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥121.19 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.3bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥19m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥18m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥442m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥728.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥704.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥994m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥203m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥784.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥755.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥29.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥895m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥436m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥709.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥684.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥24.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥678m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥764.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥734.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 574
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf | Prior1YTDDuration | -792000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -819000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -1955000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -1155000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1YTDDuration | 6977000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | CurrentYTDDuration | 1000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1YTDDuration | -40000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | CurrentYTDDuration | -934000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1YTDDuration | － | JPY |
| Payments for transfer of business2 inv cf | CurrentYTDDuration | -33000000 | JPY |
| Payments for asset retirement obligations inv cf | Prior1YTDDuration | -8000000 | JPY |
| Payments for asset retirement obligations inv cf | CurrentYTDDuration | -2000000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | -7000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -9000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 195000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 250000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -2000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 323000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | 3515000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -4590000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 721000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -881000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -1335000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -214000000 | JPY |
| Proceeds from issuance of bonds fin cf | Prior1YTDDuration | 22110000000 | JPY |
| Proceeds from issuance of bonds fin cf | CurrentYTDDuration | － | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -20000000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -6001000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -2707000000 | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf | Prior1YTDDuration | － | JPY |
| Decrease increase in deposits for purchase of treasury shares fin cf | CurrentYTDDuration | -4795000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -198000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -207000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -1071000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -1381000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -5775000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -10187000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 51672000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -25522000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 81839000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 128673000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | Prior1YTDDuration | 3000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | CurrentYTDDuration | 774000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 133516000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 103925000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 684777000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 46590000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 1178000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 2300000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |